These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27339403)

  • 1. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis.
    Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Zidan A; Oweira H
    Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e127-38. PubMed ID: 27339403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Oweira H
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):218-230. PubMed ID: 27894673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
    Wang W; Lie P; Guo M; He J
    Int J Cancer; 2017 Sep; 141(5):1018-1028. PubMed ID: 28263392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Immunotherapy; 2015; 7(11):1213-27. PubMed ID: 26513491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors.
    Abdel-Rahman O; Fouad M
    Immunotherapy; 2016 May; 8(5):665-74. PubMed ID: 27140415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
    El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
    Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Expert Opin Drug Saf; 2015 Oct; 14(10):1507-18. PubMed ID: 26394770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
    Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
    Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; Fouad M
    Ther Adv Respir Dis; 2016 Jun; 10(3):183-93. PubMed ID: 26944362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are virus-induced cancers more sensitive to checkpoint inhibitors?
    Kanaan H; Kourie HR; Awada AH
    Future Oncol; 2016 Dec; 12(23):2665-2668. PubMed ID: 27513334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.